Retrospective analysis the long-term retention rate of levetiracetam mono or combination therapy of infant ;epilepsy
10.3969/j.issn.1000-3606.2014.07.009
- VernacularTitle:左乙拉西坦单药或联合用药治疗婴儿癫癎长程保留率的回顾性分析
- Author:
Xuefei FENG
;
Yuxia CHEN
;
Ling LIU
;
Shang XIANG
;
Nong XIAO
- Publication Type:Journal Article
- Keywords:
epilepsy;
levetiraceram;
retention rate;
efifcacy;
tolerability
- From:
Journal of Clinical Pediatrics
2014;(7):633-636
- CountryChina
- Language:Chinese
-
Abstract:
Objective To analysis the long-term retention rate of Levetiraceram (LEV) monotherapy or combination therapy of infant epilepsy. Methods The clinical data of patients with infant epilepsy treated by LEV had been retrospectively analyzed from July 2006 to June 2007. Results Sixty patients with infant epilepsy treated by LEV had been recruited, 20 cases with partial seizures, 19 cases with generalized seizures, 21 cases with epilepsy syndrome. Among them 21 cases was intractable epilepsy. The retention rates of LEV in 6-month, 1-year, 2-year, 3-year and 4-year were 95.5%, 75.0%, 60.0%, 51.7%, and 38.3%. The most common reason for withdrawal was lack of effect (43.2%). COX regression model suggested that duration>1 month (RR=2.91, 95%CI:1.16~7.30) and refractory epilepsy (RR=2.30, 95%CI:1.22~4.32) were risk factors of withdrawal (all P<0.05). After treatment, the seizure frequency signiifcantly reduced compared with baseline (P<0.01). To the end of the follow-up, the efifciency was 100%and the complete remission rate was 69.57%in 23 cases continued treatment. The main side effect were fatigue (56.0%), and sleep increased, irritability, and so on. Conclusions LEV monotherapy or combination therapy has well long-term retention rate, maintains well efifcacy and tolerability in infant epilepsy.
